Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

MSQ Ventures United States

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.
Website:
http://msqventures.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
in and out licensing
Headquartner in China
No
Biotech/Pharma Category
Mr. Estigarribia Marc
MD 

Nanjing TransTherabio China

A biotech company headquartered in China with clinically validated integrated platform for drug discovery and development.  We focus on oncology and inflammatory disease. There are four projects on Phase I clinical stage.

Website:
http://www.transtherabio.com/
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
James Zhou
Director 

OncoMyx Therapeutics United States

OncoMyx Therapeutics is developing potentially best-in-class (multi-armed, IV/systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and we have demonstrated mechanism of action and combinatorial efficacy (tumor growth inhibition) when dosed IV with various checkpoint inhibitors in multiple animal models. Our company has the industry’s most experienced oncolytic virus (OV) development team and an experienced SAB, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25M series A in June 2019 to advance our lead preclinical program to IND, and among our investors are BIVF (exited OV investment ViraTx for $244M at preclinical stage in 2018) and Jonathan Lim (Ignyta CEO & current Erasca CEO). On the heels of presenting our preclinical data at SITC and announcing the appointment of Mirati CEO Chuck Baum as our new Chairperson, OncoMyx is seeking a $50M+ series B/crossover to prepare for an IPO and focus on a future transition into a clinical-stage organization. Pasted below are links to our SITC posters and some recent Fierce and BioSpace articles focused on our company.

https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/
https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer
https://www.biospace.com/article/oncomyx-s-oncolytic-virus-platform-shows-preclinical-efficacy-boosting-immunotherapy-potential/

Website:
https://www.oncomyx.com
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Fundraising and Licensing-out
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 2.38MB)
Dr. Steven Potts
Cofounder, CEO & Director 
Mr. Michael Wood
Cofounder, COO & CFO 
Functionality
Business Development
Dr. Leslie Sharp
Chief Scientific Officer 
Functionality
Research and Development

OneThree Biotech United States

My organization, OneThree Biotech, is a company that is dedicating our biology-driven AI expertise towards the fight against cancer. We’re combining systems biology with artificial intelligence to uncover new insights and build the next generation of drug discovery. We’ve built 14 different algorithms into our platform to provide insights across steps like target selection, compound mechanisms, toxicity and metabolism, and patient biomarkers at the beginning of the development process. This not only provides greater mechanistic insights, but also helps ensure a greater success rate for drugs entering preclinical development. Over the course of 2020 our founders have spoken at countless events like the BioData World Congress, Pharma and Patient USA, and various Reuters events culminating in our most recent accomplishment of winning Reuters' Entrepreneur Award for Health Solutions.
Website:
https://onethree.bio
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
To generate new insights to accelerate our partner's internal R&D or identify new candidates to fill partner's pipeline. Together we can discover new medicines at an unprecedented scale.
Headquartner in China
No
Biotech/Pharma Category
Mr. Abhinav Subramaniam
Strategy and Operations Associate 
Functionality
Management

OrigiMed China

Leading big-data- driven precision medicine pioneer
Website:
Www.origimed.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Camille Hu
Strategic Marketing 

Ouroboros Group United States

Private investment firm
Website:
www.ouroborosgroupllc.com
Company Size (Fulltime employees)
1-10
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
Find investment targets
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Dr. Richard Tannenbaum
Managing Partner 
Functionality
Investment

Photonfund China

Photon Fund is a venture capital institution concentrating on technology and innovation. Strategically located in Shenzhen, with office in Beijing and Silicon Valley, which are the most creative cities, Photon Fund invests in global scale.
Website:
http://www.photonfund.cn/gl_sn/home/index/index.html#
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
玮 肖
董事总经理 

Pierre Fabre Medicament China China

A French PHARMA & cosmetics company
Website:
www.Pierre-Fabre.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Linda Zheng
Senior Market Access & Health Economics Director 

Pleiogenix United States

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial disease that Pleiogenix is targeting is alcoholic hepatitis (AH), with additional diseases to follow (COVID-19, Fibrosis, and NASH) . AH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. The global and US prevalence is 20-25%. The AH market is estimated to be $1.2 Billion in 2025, having a current annual growth rate of 6% (2019-2025). There are no approved efficacious therapeutics for the prevention or treatment of AH (dexamethasone reduces inflammation). The target patients for therapy include those with moderate and severe forms of AH. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic, and multiple metabolic clinical benefits. In patients suffering from AH, inflammation is severely increased. In animal models of NASH, increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical that exhibits multiple beneficial effects, in the context of AH.
Website:
www.pleiogenix.com (under construction)
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Fundraising (Seed Round)
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
PLG888|Orally-available, Phase 2A-ready drug candidate|alcoholic hepatitis|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Assets Information 2
PLG888|ailable, Phase 2A-ready drug candidate|COVID-19; prevent /reduce cytokine storm|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Assets Information 3
PLG888|Orally-available, Phase 2A-ready drug candidate|non-alcoholic steatohepatitis (NASH); Fibrosis diseases|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Biotech/Pharma Asset Stage
Dr. Joseph Evans
CEO & President 
Functionality
Management

Polaris Strategic Partners United States

An innovative company to partner with emerging biotech companies in drug clinical development and commercialization through United States and China alliance of drug development.
Website:
https://polaris-strategicpartners.com/
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Jane Fang
CEO